Navicixizumab is a bispecific monoclonal antibody targeting DLL4 and VEGF, with potential anti-angiogenic and antineoplastic activities. It has shown antitumor effects in multiple cancer types, with the most promising results in ovarian cancer. M.W 146.17 kDa